Adverse Event Reporting Patterns Associated with Concomitant Use of 5-HT3 and NK-1 Receptor Antagonists: A Large-Scale Spontaneous-Reporting Analysis.
- 1The Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Shenzhen 518033, China.
- 2The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
- 3Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macao 999078, China.
Abstract
Background/Objectives: Chemotherapy-induced nausea and vomiting (CINV) is common and compromises quality of life and adherence. 5-HT3 receptor antagonists (RAs) and NK-1 RAs are cornerstones, yet adverse event patterns associated with their concomitant use are not well characterized. Methods: We queried the US Food and Drug Administration Adverse Event Reporting System (FAERS) from 2004 Q1-2025 Q1 and deduplicated reports per Food and Drug Administration (FDA) guidance. Five algorithms-the Ω shrinkage measure, additive model, multiplicative model, combination risk ratio, and chi-square model-detected disproportionate reporting signals associated with concomitant use. We also performed time-to-onset (TTO) analysis and logistic regression. Results: We identified 965 concurrent use cases with a mean age of 58 years and a mean weight of 70 kg, with 59.7% (n = 575) of these cases being female. These reports included 366 preferred terms (PTs). Forty-nine PTs were significant across all five algorithms, mainly skin and subcutaneous disorders, hypersensitivity reactions, blood pressure abnormalities, hepatic and renal impairment, and nervous system disorders, with additional signals for abnormal antidiuretic hormone secretion, respiratory disorders, and oropharyngeal disorders. TTO showed most adverse drug events (ADEs) occurred within 20 days of therapy initiation. Logistic regression indicated that older age was associated with higher odds of classification as an important medical event (IME). Conclusions: Beyond prescribing information, we detected previously unrecognized adverse event terms that were disproportionately reported with concomitant use and that merit attention in practice.
Related
- Co-Occurrence Patterns of Symptom and Functional Burden Associated with Tofacitinib and Upadacitinib: A Multidimensional Analysis of Spontaneous Reports in Rheumatoid Arthritis.
- Immune-effector and infection-associated reporting patterns of CD20×CD3 bispecific antibodies in B-cell lymphoma: a label-anchored FAERS analysis with descriptive JADER contextualization
- Reporting signals of selected extrapyramidal adverse events with four newer second-generation antipsychotics: a disproportionality analysis of FAERS spontaneous reports
- Frequency, causes, and duration of drug shortages in South Korea, 2018–2024: a nationwide descriptive analysis of regulatory reporting data and temporal patterns across the COVID-19 pandemic
- Plasma Exchange-Responsive Bulbar Dysfunction in Thymoma-Associated Myasthenia Gravis with Concomitant Lambert-Eaton Myasthenic Syndrome
BibTeX
@article{zhao2026adverse,
title = {{Adverse Event Reporting Patterns Associated with Concomitant Use of 5-HT3 and NK-1 Receptor Antagonists: A Large-Scale Spontaneous-Reporting Analysis.}},
author = {Ruiqi Zhao and Shiqi Tang and Mengyao Han and Hui Hu and Jiesheng Guo and Minling Lv and Jialing Sun and Xiaozhou Zhou},
journal = {Pharmaceuticals (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/ph19101626},
url = {https://europepmc.org/article/MED/42943323},
note = {CC BY},
}
RIS
TY - JOUR
TI - Adverse Event Reporting Patterns Associated with Concomitant Use of 5-HT3 and NK-1 Receptor Antagonists: A Large-Scale Spontaneous-Reporting Analysis.
AU - Ruiqi Zhao
AU - Shiqi Tang
AU - Mengyao Han
AU - Hui Hu
AU - Jiesheng Guo
AU - Minling Lv
AU - Jialing Sun
AU - Xiaozhou Zhou
PY - 2026
DA - 2026/10/14
JO - Pharmaceuticals (Basel, Switzerland)
DO - 10.3390/ph19101626
UR - https://europepmc.org/article/MED/42943323
AB - Background/Objectives: Chemotherapy-induced nausea and vomiting (CINV) is common and compromises quality of life and adherence. 5-HT3 receptor antagonists (RAs) and NK-1 RAs are cornerstones, yet adverse event patterns associated with their concomitant use are not well characterized. Methods: We queried the US Food and Drug Administration Adverse Event Reporting System (FAERS) from 2004 Q1-2025 Q1 and deduplicated reports per Food and Drug Administration (FDA) guidance. Five algorithms-the Ω shrinkage measure, additive model, multiplicative model, combination risk ratio, and chi-square model-detected disproportionate reporting signals associated with concomitant use. We also performed time-to-onset (TTO) analysis and logistic regression. Results: We identified 965 concurrent use cases with a mean age of 58 years and a mean weight of 70 kg, with 59.7% (n = 575) of these cases being female. These reports included 366 preferred terms (PTs). Forty-nine PTs were significant across all five algorithms, mainly skin and subcutaneous disorders, hypersensitivity reactions, blood pressure abnormalities, hepatic and renal impairment, and nervous system disorders, with additional signals for abnormal antidiuretic hormone secretion, respiratory disorders, and oropharyngeal disorders. TTO showed most adverse drug events (ADEs) occurred within 20 days of therapy initiation. Logistic regression indicated that older age was associated with higher odds of classification as an important medical event (IME). Conclusions: Beyond prescribing information, we detected previously unrecognized adverse event terms that were disproportionately reported with concomitant use and that merit attention in practice.
SN - 1424-8247
ER -